As U.S. News tweaks methodology, top four cancer hospitals remain unchanged from last year (1) MD Anderson, (2) MSK, (3) Mayo, (4) DFCI

Cigall Kadoch wins $250,000 Blavatnik National Award

Cigall Kadoch was named the laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences for her work in cancer biology.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Combination therapy shows reduced agitated delirium in patients with advanced cancers

Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.

September 20, 2024

Vol.50 No.35

Clinical

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

September 13, 2024

Vol.50 No.34

By McKenzie Prillaman

Tumors are able to form with no DNA mutations, fly study shows

Tumors are able to form without any DNA mutations, according to a recent proof-of-principle study performed in flies. Epigenetic changes alone—even temporary alterations—induced permanent cancer cell fate.

Mayo Clinic receives $50M from Stephen M. and Barbara J. Slaggie to expand cancer care access

Mayo Clinic received a $50 million investment from Stephen M. and Barbara J. Slaggie of Marco Island, FL, and Winona, MN.

September 13, 2024

Vol.50 No.34

In Brief

CPRIT awards over $60M in grants

The Cancer Prevention and Research Institute of Texas approved $60.6 million in grants.

September 13, 2024

Vol.50 No.34

As U.S. News tweaks methodology, top four cancer hospitals remain unchanged from last year

(1) MD Anderson, (2) MSK, (3) Mayo, (4) DFCI

YOU MAY BE INTERESTED IN

Cigall Kadoch wins $250,000 Blavatnik National Award

Combination therapy shows reduced agitated delirium in patients with advanced cancers

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Tumors are able to form with no DNA mutations, fly study shows

Mayo Clinic receives $50M from Stephen M. and Barbara J. Slaggie to expand cancer care access

CPRIT awards over $60M in grants

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

As U.S. News tweaks methodology, top four cancer hospitals remain unchanged from last year

(1) MD Anderson, (2) MSK, (3) Mayo, (4) DFCI

YOU MAY BE INTERESTED IN

Cigall Kadoch wins $250,000 Blavatnik National Award

Combination therapy shows reduced agitated delirium in patients with advanced cancers

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Tumors are able to form with no DNA mutations, fly study shows

Mayo Clinic receives $50M from Stephen M. and Barbara J. Slaggie to expand cancer care access

CPRIT awards over $60M in grants

Can you spare 10 minutes to complete a survey?

Login

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies